Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
Health Professionals
Retrospective Analysis Across Six CheckMate Trials Reinforces Benefit of Nivolumab Plus Ipilimumab
A pooled analysis of six CheckMate studies in immune checkpoint inhibitor (ICI), specifically treatment with nivolumab plus ipilimumab (NIVO + IPI) versus NIVO monotherapy, aimed to describe the long-term overall survival in patients with ICI treatment-naïve unresectable/metastatic melanoma.
From melanoma to malaria: photoacoustic device detects disease without taking a single drop of blood
Malaria remains a serious health concern, with annual deaths increasing yearly since 2019 and almost half of the world’s population at risk of infection.
Vidutolimod Plus Nivolumab Proves Active in High-Risk, Resectable Melanoma
The combination of vidutolimod and nivolumab demonstrated activity in a phase 2 trial of patients with high-risk, resectable melanoma, according to researchers. They reported these findings in Cancer Cell.